MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - TEVA PHARMA (Israel)
VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 VENUS REMEDIES  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
TEVA PHARMA Dec-13 |
VENUS REMEDIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 3,050 | - | |
| Low | Rs | 61 | 2,650 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 1,750.4 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | 109.3 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | 250.8 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 95.72 | - | |
| Dividend yield (eoy) | % | 0 | 3.4 | 0.0% | |
| Book value per share (Unadj.) | Rs | 293.3 | 1,944.4 | - | |
| Shares outstanding (eoy) | m | 12.34 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 1.6 | 19.0% | |
| Avg P/E ratio | x | -3.8 | 26.1 | -14.4% | |
| P/CF ratio (eoy) | x | 36.7 | 11.4 | 323.4% | |
| Price / Book Value ratio | x | 0.3 | 1.5 | 21.8% | |
| Dividend payout | % | 0 | 87.5 | 0.0% | |
| Avg Mkt Cap | Rs m | 1,154 | 2,416,571 | 0.0% | |
| No. of employees | `000 | 0.9 | 44.9 | 2.1% | |
| Total wages/salary | Rs m | 393 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,026.1 | 33,025.8 | 12.2% | |
| Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
| Avg. net profit/employee | Rs Th | -331.8 | 2,063.1 | -16.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 1,484,344 | 0.3% | |
| Other income | Rs m | 23 | 0 | - | |
| Total revenues | Rs m | 3,747 | 1,484,344 | 0.3% | |
| Gross profit | Rs m | 395 | 406,488 | 0.1% | |
| Depreciation | Rs m | 338 | 119,981 | 0.3% | |
| Interest | Rs m | 354 | 29,155 | 1.2% | |
| Profit before tax | Rs m | -275 | 257,353 | -0.1% | |
| Minority Interest | Rs m | 0 | 1,169 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -168,938 | 0.0% | |
| Tax | Rs m | 32 | -3,142 | -1.0% | |
| Profit after tax | Rs m | -307 | 92,726 | -0.3% | |
| Gross profit margin | % | 10.6 | 27.4 | 38.7% | |
| Effective tax rate | % | -11.5 | -1.2 | 940.2% | |
| Net profit margin | % | -8.2 | 6.2 | -131.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 1,002,520 | 0.3% | |
| Current liabilities | Rs m | 2,305 | 874,283 | 0.3% | |
| Net working cap to sales | % | 8.9 | 8.6 | 103.5% | |
| Current ratio | x | 1.1 | 1.1 | 99.8% | |
| Inventory Days | Days | 135 | 91 | 149.2% | |
| Debtors Days | Days | 46 | 96 | 48.3% | |
| Net fixed assets | Rs m | 4,871 | 484,819 | 1.0% | |
| Share capital | Rs m | 123 | 3,654 | 3.4% | |
| Net worth | Rs m | 3,619 | 1,648,825 | 0.2% | |
| Long term debt | Rs m | 1,374 | 758,978 | 0.2% | |
| Total assets | Rs m | 7,509 | 3,392,202 | 0.2% | |
| Interest coverage | x | 0.2 | 9.8 | 2.3% | |
| Debt to equity ratio | x | 0.4 | 0.5 | 82.5% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 113.3% | |
| Return on assets | % | 0.6 | 3.6 | 17.6% | |
| Return on equity | % | -8.5 | 5.6 | -150.8% | |
| Return on capital | % | 1.6 | 4.9 | 32.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 236,528 | 0.2% | |
| From Investments | Rs m | -123 | -83,811 | 0.1% | |
| From Financial Activity | Rs m | -387 | -283,731 | 0.1% | |
| Net Cashflow | Rs m | 4 | -131,015 | -0.0% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.07 Rs / USD
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare VENUS REMEDIES With: AJANTA PHARMA STERLING BIOTECH NATCO PHARMA TTK HEALTHCARE AUROBINDO PHARMA
Today's Market
Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)
Jun 12, 2019 | Updated on Jun 12, 2019For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
